Evolent Health (EVH) Receivables (2015 - 2026)

Evolent Health has reported Receivables for 12 years, with the latest figure at $315.0 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables fell 28.52% year-over-year to $315.0 million; the trailing twelve-month figure through Mar 2026 stood at $315.0 million (down 28.52% YoY), and the FY2025 full-year result was $311.0 million, down 26.12% from the prior year.
• Receivables for Q1 2026 stood at $315.0 million, up from $311.0 million in the prior quarter.
• The five-year high for Receivables was $472.4 billion in Q4 2023, with the low at $127.7 million in Q2 2022.
• Average Receivables over 5 years is $28.1 billion, with a median of $366.2 million recorded in 2023.
• Year-over-year, Receivables surged 175429.54% in 2023 and plunged 99.91% in 2024.
• Tracing EVH's Receivables over 5 years: stood at $269.1 million in 2022, then surged by 175429.54% to $472.4 billion in 2023, then sank by 99.91% to $420.9 million in 2024, then decreased by 26.12% to $311.0 million in 2025, then gained by 1.31% to $315.0 million in 2026.
• The last three Receivables figures came in at $315.0 million (Q1 2026), $311.0 million (Q4 2025), and $386.6 million (Q3 2025), per Business Quant data.

Peer Comparison